Overview of the metallometabolomic methodology for metal-based drug metabolism

Current Drug Metabolism

Volumn 12, Issue 3, 2011, Pages 287-299

  Ge, Ruiguang ^a   Sun, Xuesong ^b   He, Qing Yu ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b JINAN UNIVERSITY   (China)

Author keywords

Cellular localization; Metallodrug; Metallometabolite; Metallometabolomics; Structural elucidation

Indexed keywords

CARBOPLATIN; CISPLATIN; INDAZOLIUM TETRACHLOROBIS(INDAZOLE)RUTHENATE; OXALIPLATIN; PLATINUM; RUTHENIUM DERIVATIVE; SELENIUM; UNCLASSIFIED DRUG;

ARTICLE; CAPILLARY ELECTROPHORESIS; DRUG METABOLISM; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLOMICS; METALLOMETABOLOMIC; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; X RAY ABSORPTION SPECTROSCOPY; X RAY DIFFRACTION; X RAY FLUORESCENCE;

ANIMALS; CHEMISTRY TECHNIQUES, ANALYTICAL; HUMANS; METALS; MOLECULAR CONFORMATION; PHARMACEUTICAL PREPARATIONS;

EID: 79953645557     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920011795101813     Document Type: Article

References (130)

1. Orvig, C.; Abrams, M.J. Medicinal inorganic chemistry: introduction. Chem. Rev., 1999, 99(9), 2201-2204.
2. Rosenberg, B.; VanCamp, L.; Trosko, J.E.; Mansour, V.H. Platinum compounds: a new class of potent antitumour agents. Nature, 1969, 222(5191), 385-386.
3. Todd, R.C.; Lippard, S.J. Inhibition of transcription by platinum antitumor compounds. Metallomics, 2009, 1(4), 280-91.
4. Guo, Z.; Sadler, P.J. Metals in medicine. Angew. Chem. Int. Ed. Engl., 1999, 38(11), 1513-1531. (Pubitemid 29288755)
5. Ge, R.; Sun, H. Bioinorganic chemistry of bismuth and antimony: target sites of metallodrugs. Acc. Chem. Res., 2007, 40(4), 267-74.
6. Woolf, T.F. Handbook of drug metabolism; Marcel Dekker: New York, 1999.
7. Uetrecht, J.P.; Trager, W. Drug Metabolism: Chemical and Enzymatic Aspects; Informa Healthcare: New York, 2007.
8. Sun, X.; Tsang, C.N.; Sun, H. Identification and characterization of metallodrug binding proteins by (metallo)proteomics. Metallomics, 2009, 1(1), 25-31.
9. Cepeda, V.; Fuertes, M.A.; Castilla, J.; Alonso, C.; Quevedo, C.; Perez, J.M. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med. Chem., 2007, 7(1), 3-18. (Pubitemid 46062402)
10. Wang, D.; Lippard, S.J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov., 2005, 4(4), 307-320. (Pubitemid 41130944)
11. Timerbaev, A.R.; Hartinger, C.G.; Aleksenko, S.S.; Keppler, B.K. Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology. Chem. Rev., 2006, 106(6), 2224-2248.
12. Caravan, P.; Cloutier, N.J.; Greenfield, M.T.; McDermid, S.A.; Dunham, S.U.; Bulte, J.W.; Amedio, J.C., Jr.; Looby, R.J.; Supkowski, R.M.; Horrocks, W.D., Jr.; McMurry, T.J.; Lauffer, R.B. The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. J. Am. Chem. Soc., 2002, 124(12), 3152-3162. (Pubitemid 34249987)
13. Suzuki, K.T. Metabolomics of arsenic based on speciation studies. Anal. Chim. Acta, 2005, 540(1), 71-6. (Pubitemid 40693107)
14. Szpunar, J. Advances in analytical methodology for bioinorganic speciation analysis: metallomics, metalloproteomics and heteroatomtagged proteomics and metabolomics. Analyst, 2005, 130(4), 442-65. (Pubitemid 40523241)
15. Gardea-Torresdey, J.L.; Peralta-Videa, J.R.; de la Rosa, G.; Parsons, J.G. Phytoremediation of heavy metals and study of the metal coordination by X-ray absorption spectroscopy. Coord. Chem. Rev., 2005, 249(17-18), 1797-1810. (Pubitemid 41121955)
16. Sekhon, B.S. Metallomics - an overview. Proc. Natl. Acad. Sci. India B, 2008, 78(4), 299-313.
17. Mounicou, S.; Szpunar, J.; Łobinśki, R. Metallomics: the concept and methodology. Chem. Soc. Rev., 2009, 2009(4), 1119-1138.
18. Mounicou, S.; Szpunar, J.; Łobin śki, R. Inductively-coupled plasma mass spectrometry in proteomics, metabolomics and metallomics studies. Eur. J. Mass Spectrom. (Chichester, Eng), 2010, 16(3), 243-253.
19. Koningsberger, D.C.; Prins, R. X-ray Absorption: Principles, Applications, Techniques of EXAFS, SEXAFS, and XANES; Wiley: New York, 1988.
20. Ascone, I.; Fourme, R.; Hasnain, S.; Hodgson, K. Metallogenomics and biological X-ray absorption spectroscopy. J. Synchrotron Radiat., 2005, 12(1), 1-3. (Pubitemid 41556781)
21. Zhang, C.X.; Lippard, S.J. New metal complexes as potential therapeutics. Curr. Opin. Chem. Biol., 2003, 7(4), 481-489. (Pubitemid 36980839)
22. Farrell, N. Polynuclear platinum drugs. Met. Ions Biol. Syst., 2004, 42(1), 251-196.
23. Jung, Y.; Lippard, S.J. Direct cellular responses to platinuminduced DNA damage. Chem. Rev., 2007, 107(5), 1387-1407. (Pubitemid 46864967)
24. Reedijk, J. New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA. Proc. Natl. Acad. Sci. USA, 2003, 100(7), 3611-3616. (Pubitemid 36422584)
25. Hall, M.D.; Foran, G.J.; Zhang, M.; Beale, P.J.; Hambley, T.W. XANES determination of the platinum oxidation state distribution in cancer cells treated with platinum(IV) anticancer agents. J. Am. Chem. Soc., 2003, 125(25), 7524-7525. (Pubitemid 36750267)
26. Hellquist, B.; Bengtsson, L.A.; Holmberg, B.; Hedman, B.; Persson, I.; Elding, L.I. Structures of solvated cations of palladium(II)and platinum(II) in dimethyl sulfoxide, acetonitrile and aqueous solution studied by EXAFS and LAXS. Acta Chem. Scand., 1991, 45(1), 449-455.
27. Ayala, R.; Marcos, E.S.; Diaz-Moreno, S.; Sole, V.A.; Munoz- Paez, A. Geometry and hydration structure of Pt(II) square planar complexes [Pt(H2O)4]2+ and [PtCl4]2+ as studied by X-ray absorption spectroscopies and quantum-mechanical computions. J. Phys. Chem. B, 2001, 105(31), 7588-7593. (Pubitemid 35338934)
28. Jalilehvand, F.; Laffin, L.J. Structure of the hydrated platinum(II) ion and the cis-diammineplatinum(II) complex in acidic aqueous solution: an EXAFS study. Inorg. Chem., 2008, 47(8), 3248-3254.
29. Helm, L.; Elding, L.I.; Merbach, A.E. High-pressure NMR kinetics. 21. activation parameters and mechanism for water exchange of tetraaquaplatinum(II) studied by high-pressure oxygen-17 NMR spectroscopy. Inorg. Chem., 1985, 24(11), 1719-1721.
30. Ascone, I.; Messori, L.; Casini, A.; Gabbiani, C.; Balerna, A.; Dell'Unto, F.; Castellano, A.C. Exploiting soft and hard X-ray absorption spectroscopy to characterize metallodrug/protein interactions: the binding of [trans-RuCl4(Im)(dimethylsulfoxide)][ImH] (Im = imidazole) to bovine serum albumin. Inorg. Chem., 2008, 47(19), 8629-8634.
31. Ravera, M.; Baracco, S.; Cassino, C.; Colangelo, D.; Bagni, G.; Sava, G.; Osella, D. Electrochemical measurements confirm the preferential bonding of the antimetastatic complex [ImH][RuCl(4)(DMSO)(Im)] (NAMI-A) with proteins and the weak interaction with nucleobases. J. Inorg. Biochem., 2004, 98(6), 984-990. (Pubitemid 38638494)
32. Groessl, M.; Reisner, E.; Hartinger, C.G.; Eichinger, R.; Semenova, O.; Timerbaev, A.R.; Jakupec, M.A.; Arion, V.B.; Keppler, B.K. Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-DMSO)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4- triazole): aquation, redox properties, protein binding, and antiproliferative activity. J. Med. Chem., 2007, 50(9), 2185-2193.
33. Reisner, E.; Arion, V.B.; Keppler, B.K.; Pombeiro, A.J.L. Electrontransfer activated metal-based anticancer drugs. Inorg. Chim. Acta, 2008, 361(6), 1569-1583.
34. Messori, L.; Orioli, P.; Vullo, D.; Alessio, E.; Iengo, E. A spectroscopic study of the reaction of NAMI, a novel ruthenium(III) antineoplastic complex, with bovine serum albumin. Eur. J. Biochem., 2000, 267(4), 1206-1213. (Pubitemid 30108341)
35. Wüthrich, K. Protein structure determination in solution by NMR spectroscopy. J. Biol. Chem., 1990, 265(36), 22059-62. (Pubitemid 120014262)
36. Griffin, J.L.; Shockcor, J.P. Metabolic profiles of cancer cells. Nat. Rev. Cancer, 2004, 4(7), 551-561. (Pubitemid 38868624)
37. Prakash, C.; Shaffer, C.L.; Nedderman, A. Analytical strategies for identifying drug metabolites. Mass Spectrom. Rev., 2007, 26(3), 340-369. (Pubitemid 46750374)
38. Vinje, J.; Sletten, E. NMR spectroscopy of anticancer platinum drugs. Anticancer Agents Med. Chem., 2007, 7(1), 35-54. (Pubitemid 46062404)
39. Berners-Price, S.J.; Sadler, P.J. Coordination chemistry of metallodrugs: insights into biological speciation from NMR spectroscopy. Coord. Chem. Rev., 1996, 151(3-4), 1-40.
40. Bax, A.; Griffey, H.; Hawkins, B.L. Correlation of proton and nitrogen-15 chemical shifts by multiple quantum NMR. J. Magn. Reson., 1983, 55(2), 301-315.
41. Horacek, P.; Drobnik, J. Interaction of cisdichlorodiammineplatinum (II) with DNA. Biochim. Biophys. Acta, 1971, 254(2), 341-347.
42. Barnham, K.J.; Sadler, P.J.; Berners-Price, S.J.; Frenkeil, T.A.; Frey, U. Platination pathways for reactions of cisplatin with GG single-stranded and double-stranded decanucleotides. Angew. Chem. Int. Ed. Engl., 1995, 34(17), 1874-1877.
43. Legendre, F.; Bas, V.; Kozelka, J.; Chottard, J.C. A complete kinetic study of GG versus AG plantination suggests that the doubly aquated derivatives of cisplatin are the actual DNA binding species. Chemistry (Weinheim an der Bergstrasse, Germany), 2000, 6(11), 2002-2010.
44. Davies, M.S.; Berners-Price, S.J.; Hambley, T.W. Slowing of cisplatin aquation in the presence of DNA but not in the presence of phosphate: improved understanding of sequence selectivity and the roles of monoaquated and diaquated species in the binding of cisplatin to DNA. Inorg. Chem., 2000, 39(25), 5603-5613. (Pubitemid 32065704)
45. Centerwall, C.R.; Goodisman, J.; Kerwood, D.J.; Dabrowiak, J.C. Cisplatin carbonato complexes. Implications for uptake, antitumor properties, and toxicity. J. Am. Chem. Soc., 2005, 127(37), 12768-12769. (Pubitemid 41339143)
46. Vinje, J.; Parkinson, J.A.; Sadler, P.J.; Brown, T.; Sletten, E. Sequence-selective metalation of double-helical oligodeoxyribonucleotides with PtII, MnII, and ZnII ions. Chemistry (Weinheim an der Bergstrasse, Germany), 2003, 9(7), 1620-1630.
47. Blommaert, F.A.; van Dijk-Knijnenburg, H.C.; Dijt, F.J.; den Engelse, L.; Baan, R.A.; Berends, F.; Fichtinger-Schepman, A.M. Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells. Biochemistry, 1995, 34(26), 8474-8480.
48. Frey, U.; Ranford, J.D.; Sadler, P.J. Ring-opening reactions of the anticancer drug carboplain: NMR characterization of cis-Pt(NH3)2(CBDCA-O) (5′-GMP-N7) in solution. Inorg. Chem., 1993, 32(8), 1333-13340.
49. Knox, R.J.; Friedlos, F.; Lydall, D.A.; Roberts, J.J. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cisdiamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato) platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res., 1986, 46(4), 1972-1979. (Pubitemid 16080411)
50. Barnham, K.J.; Djuran, M.I.; Murdoch, P.S.; Ranford, J.D.; Sadler, P.J. Ring-opened adducts of the anticancer drug carboplatin with sulfur amino acids. Inorg. Chem., 1996, 35(4), 1065-1072. (Pubitemid 126460616)
51. Barnham, K.J.; Frey, U.; Murdoch, P.D.; Ranford, J.D.; Sadler, P.J. Pt(CBDCA-O)(NH3)2(L-methionine-S): ring-opened adduct of the anticancer drug carboplatin. Detection of a similar complex in urine by NMR spectroscopy. J. Am. Chem. Soc., 1994, 116(24), 11175-11176.
52. Coluccia, M.; Nassi, A.; Loseto, F.; Boccarelli, A.; Mariggio, M.A.; Giordano, D.; Intini, F.P.; Caputo, P.; Natile, G. A transplatinum complex showing higher antitumor activity than the cis congeners. J. Med. Chem., 1993, 36(4), 510-2. (Pubitemid 23065311)
53. Casini, A.; Gabbiani, C.; Mastrobuoni, G.; Pellicani, R.Z.; Intini, F.P.; Arnesano, F.; Natile, G.; Moneti, G.; Francese, S.; Messori, L. Insights into the molecular mechanisms of protein platination from a case study: the reaction of anticancer platinum(II) iminoethers with horse heart cytochrome c. Biochemistry, 2007, 46(43), 12220-12230. (Pubitemid 350022376)
54. Bettmer, J. Application of isotope dilution ICP-MS techniques to quantitative proteomics. Anal. Bioanal. Chem., 2010, 397(8), 3495-3502.
55. Wang, M.; Feng, W.Y.; Zhao, Y.L.; Chai, Z.F. ICP-MS-based strategies for protein quantification. Mass Spectrom. Rev., 29(2), 326-348.
56. Oliveira, E.J.; Watson, D.G. Liquid chromatography-mass spectrometry in the study of the metabolism of drugs and other xenobiotics. Biomed. Chromatogr., 2000, 14(6), 351-372.
57. Ma, S.; Chowdhury, S.K.; Alton, K.B. Application of mass spectrometry for metabolite identification. Curr. Drug Metab., 2006, 7(5), 503-523.
58. Prange, A.; Schaumlöffel, D. Hyphenated techniques for the characterization and quantification of metallothionein isoforms. Anal. Bioanal. Chem., 2002, 373(6), 441-453. (Pubitemid 34969494)
59. Spezia, S.; Bocca, B.; Forte, G.; Gatti, A.; Mincione, G.; Ronchi, A.; Bavazzano, P.; Alimonti, A.; Minoia, C. Comparison of inductively coupled plasma mass spectrometry techniques in the determination of platinum in urine: quadrupole vs. sector field. Rapid Commun. Mass Spectrom., 2005, 19(11), 1551-1556. (Pubitemid 40801999)
60. Michalke, B. Platinum speciation used for elucidating activation or inhibition of Pt-containing anti-cancer drugs. J. Trace Elem. Med. Biol., 2010, 24(2), 69-77.
61. Gammelgaard, B.; Hansen, H.R.; Stürup, S.; Møller, C. The use of inductively coupled plasma mass spectrometry as a detector in drug metabolism studies. Expert Opin. Drug Metab. Toxicol., 2008, 4(9), 1187-1207.
62. Oe, T.; Tian, Y.; O'Dwyer, P.J.; Roberts, D.W.; Malone, M.D.; Bailey, C.J.; Blair, I.A. A validated liquid chromatography/tandem mass spectrometry assay for cis-amminedichloro(2-methylpyridine) platinum(II) in human plasma ultrafiltrate. Anal. Chem., 2002, 74(3), 591-599. (Pubitemid 34131509)
63. Oe, T.; Tian, Y.; O'Dwyer, P.J.; Roberts, D.W.; Bailey, C.J.; Blair, I.A. Determination of the platinum drug cis-amminedichloro(2-ethylpyridine) platinum(II) in human urine by liquid chromatography- tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2003, 792(2), 217-227. (Pubitemid 36830872)
64. Smith, C.J.; Wilson, I.D.; Abou-Shakra, F.; Payne, R.; Grisedale, H.; Long, A.; Roberts, D.; Malone, M. Analysis of [14C]-labelled platinum anticancer compounds in dosing formulations and urine using a combination of HPLC-ICPMS and flow scintillation counting. Chromatographia, 2002, 55(Suppl 1), S151-5. (Pubitemid 34548126)
65. Smith, C.J.; Wilson, I.D.; Abou-Shakra, F.; Payne, R.; Parry, T.C.; Sinclair, P.; Roberts, D.W. A comparison of the quantitative methods for the analysis of the platinum-containing anticancer drug [cis- [amminedichloro(2- methylpyridine)]platinum(II)] (ZD0473) by HPLC coupled to either a triple quadrupole mass spectrometer or an inductively coupled plasma mass spectrometer. Anal. Chem., 2003, 75(6), 1463-1469. (Pubitemid 36397181)
66. Allain, P.; Heudi, O.; Cailleux, A.; Le Bouil, A.; Larra, F.; Boisdron- Celle, M.; Gamelin, E. Early biotransformations of oxaliplatin after its intravenous administration to cancer patients. Drug Metab. Dispos., 2000, 28(11), 1379-1384.
67. Urien, S.; Tillement, J.P. In vitro binding of oxaliplatin to human serum proteins. Drug Interact. Intern. Rapp. Sanofi Winthrop, 1995, LPH 0022(1), 125-127.
68. Xie, R.; Johnson, W.; Rodriguez, L.; Gounder, M.; Hall, G.S.; Buckley, B. A study of the interactions between carboplatin and blood plasma proteins using size exclusion chromatography coupled to inductively coupled plasma mass spectrometry. Anal. Bioanal. Chem., 2007, 387(8), 2815-2822. (Pubitemid 46479944)
69. Mandal, R.; Kalke, R.; Li, X.F. Interaction of oxaliplatin, cisplatin, and carboplatin with hemoglobin and the resulting release of a heme group. Chem. Res. Toxicol., 2004, 17(10), 1391-1397. (Pubitemid 39391217)
70. Mandal, R.; Kalke, R.; Li, X.F. Mass spectrometric studies of cisplatin- induced changes of hemoglobin. Rapid Commun. Mass Spectrom., 2003, 17(24), 2748-2754. (Pubitemid 38029315)
71. Esteban-Fernández, D.; Cañas, B.; Pizarro, I.; Palacios, M.A.; Gómez-Gómez, M.M. SEC-ICP-MS and ESI-MS as tools to study the interaction between cisplatin and cytosolic biomolecules. J. Anal. At. Spectrom., 2007, 22(9), 1113-1121. (Pubitemid 47311274)
72. Falta, T.H.; Koellensperger, G.; Standler, A.; Buchberger, W.; Mader, R.M.; Hann, S. Quantification of cisplatin, carboplatin and oxaliplatin in spiked human plasma samples by ICP-SFMS and hydrophilic interaction liquid chromatography (HILIC) combined with ICP-MS detection. J. Anal. At. Spectrom., 2009, 24(10), 1336-1342.
73. Suzuki, K.T.; Mandal, B.K.; Ogra, Y. Speciation of arsenic in body fluids. Talanta, 2002, 58(1), 111-119. (Pubitemid 34857387)
74. Aposhian, H.V.; Zakharyan, R.A.; Avram, M.D.; Sampayo-Reyes, A.; Wollenberg, M.L. A review of the enzymology of arsenic metabolism and a new potential role of hydrogen peroxide in the detoxication of the trivalent arsenic species. Toxicol. Appl. Pharmacol., 2004, 198(3), 327-335. (Pubitemid 38969962)
75. Challenger, F. Biological methylation. Q. Rev. Chem. Soc., 1955, 9(3), 255-286.
76. Zhang, T.D. Treatment of acute granulocytic leukemia with "Ai ling No. 1"-clinical analysis and experimental research. Zhong Xi Yi Jie He Za Zhi, 1984, 4(1), 19-20.
77. Shen, Z.X.; Chen, G.Q.; Ni, J.H.; Li, X.S.; Xiong, S.M.; Qiu, Q.Y.; Zhu, J.; Tang, W.; Sun, G.L.; Yang, K.Q.; Chen, Y.; Zhou, L.; Fang, Z.W.; Wang, Y.T.; Ma, J.; Zhang, P.; Zhang, T.D.; Chen, S.J.; Chen, Z.; Wang, Z.Y. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood, 1997, 89(9), 3354-3360.
78. Šlejkovec, Z.; Falnoga, I.; Goessler, W.; van Elteren, J.T.; Raml, R.; Podgornik, H.; Černelč, P. Analytical artefacts in the speciation of arsenic in clinical samples. Anal. Chim. Acta, 2008, 607(1), 83-91. (Pubitemid 50014947)
79. Yoshino, Y.; Yuan, B.; Miyashita, S.I.; Iriyama, N.; Horikoshi, A.; Shikino, O.; Toyoda, H.; Kaise, T. Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia. Anal. Bioanal. Chem., 2009, 393(2), 689-697. (Pubitemid 50331982)
80. Fukai, Y.; Hirata, M.; Ueno, M.; Ichikawa, N.; Kobayashi, H.; Saitoh, H.; Sakurai, T.; Kinoshita, K.; Kaise, T.; Ohta, S. Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: speciation of arsenic metabolites in serum and urine. Biol. Pharm. Bull., 2006, 29(5), 1022-1027.
81. Chen, G.Q.; Zhou, L.; Styblo, M.; Walton, F.; Jing, Y.; Weinberg, R.; Chen, Z.; Waxman, S. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Res., 2003, 63(8), 1853-1859. (Pubitemid 36460848)
82. Wang, Z.; Zhou, J.; Lu, X.; Gong, Z.; Le, X.C. Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Chem. Res. Toxicol., 2004, 17(1), 95-103. (Pubitemid 38134064)
83. Kajander, E.O.; Pajula, R.L.; Harvima, R.J.; Eloranta, T.O. Synthesis and analysis of selenomethionine metabolites. Anal. Biochem., 1989, 179(2), 396-400.
84. Wrobel, K.; Wrobel, K.; Caruso, J.A. Selenium speciation in low molecular weight fraction of Se-enriched yeasts by HPLC-ICP-MS: detection of selenoadenosylmethionine. J. Anal. At. Spectrom., 2002, 17(9), 1048-1054.
85. Afton, S.E.; Catron, B.; Caruso, J.A. Elucidating the selenium and arsenic metabolic pathways following exposure to the nonhyperaccumulating Chlorophytum comosum, spider plant. J. Exp. Bot., 2009, 60(4), 1289-1297.
86. Szpunar, J.; Makarov, A.; Pieper, T.; Keppler, B.K.; Łobinś ki, R. Investigation of metallodrug-protein interactions by size-exclusion chromatography coupled with inductively coupled plasma mass spectrometry (ICP-MS). Anal. Chim. Acta, 1999, 387(2), 135-144. (Pubitemid 29172959)
87. Sulyok, M.; Hann, S.; Hartinger, C.G.; Keppler, B.K.; Stingeder, G. Two dimensional separation schemes for investigation of the interaction of an anticancer ruthenium(III) compound with plasma proteins. J. Anal. At. Spectrom., 2005, 20(9), 856-863. (Pubitemid 41284843)
88. Casini, A.; Mastrobuoni, G.; Terenghi, M.; Gabbiani, C.; Monzani, E.; Moneti, G.; Casella, L.; Messori, L. Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-tetrachloro(dimethyl sulfoxide)( imidazole)ruthenate(III) with hen egg white lysozyme and horse heart cytochrome c. J. Biol. Inorg. Chem., 2007, 12(8), 1107-1117. (Pubitemid 47594254)
89. Andersson, T.; Thulin, E.; Forsen, S. Ion binding to cytochrome c studied by nuclear magnetic quadrupole relaxation. Biochemistry, 1979, 18(12), 2487-2493.
90. Casini, A.; Gabbiani, C.; Mastrobuoni, G.; Messori, L.; Moneti, G.; Pieraccini, G. Exploring metallodrug-protein interactions by ESI mass spectrometry: the reaction of anticancer platinum drugs with horse heart cytochrome c. ChemMedChem., 2006, 1(4), 413-417.
91. Hartinger, C.G.; Timerbaev, A.R.; Keppler, B.K. Capillary electrophoresis in anti-cancer metallodrug research: advances and future challenges. Electrophoresis, 2003, 24(12-13), 2023-2037. (Pubitemid 38094243)
92. Timerbaev, A.R.; Keppler, B.K. Capillary electrophoresis of metalbased drugs. Anal. Biochem., 2007, 369(1), 1-7.
93. Álvarez-Llamas, G.; Fernandez de la Campa, M.d.R.; Sanz-Medel, A. ICP-MS for specific detection in capillary electrophoresis. Trends Anal. Chem., 2005, 24(1), 28-36. (Pubitemid 40082726)
94. Polec-Pawlak, K.; Abramski, J.K.; Semenova, O.; Hartinger, C.G.; Timerbaev, A.R.; Keppler, B.K.; Jarosz, M. Platinum group metallodrug- protein binding studies by capillary electrophoresisinductively coupled plasma-mass spectrometry: a further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins. Electrophoresis, 2006, 27(5-6), 1128-1135.
95. Timerbaev, A.R.; Foteeva, L.S.; Rudnev, A.V.; Abramski, J.K.; Polec-Pawlak, K.; Hartinger, C.G.; Jarosz, M.; Keppler, B.K. Probing the stability of serum protein-ruthenium(III) drug adducts in the presence of extracellular reductants using CE. Electrophoresis, 2007, 28(13), 2235-40. (Pubitemid 47065151)
96. Warnke, U.; Rappel, C.; Meier, H.; Kloft, C.; Galanski, M.; Hartinger, C.G.; Keppler, B.K.; Jaehde, U. Analysis of platinum adducts with DNA nucleotides and nucleosides by capillary electrophoresis coupled to ESI-MS: indications of guanosine 5′-monophosphate O6-N7 chelation. ChemBioChem., 2004, 5(11), 1543-1549. (Pubitemid 39531667)
97. Gammelgaard, B.; Hansen, H.R.; Stürup, S.; Moller, C. The use of inductively coupled plasma mass spectrometry as a detector in drug metabolism studies. Expert Opin. Drug Metab. Toxicol., 2008, 4(9), 1187-1207.
98. Schluga, P.; Hartinger, C.G.; Egger, A.; Reisner, E.; Galanski, M.; Jakupec, M.A.; Keppler, B.K. Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP. Dalton Trans., 2006, 2006(14), 1796-1802.
99. Prange, A.; Pröfrock, D. Application of CE-ICP-MS and CE-ESIMS in metalloproteomics: challenges, developments, and limitations. Anal. Bioanal. Chem., 2005, 383(3), 372-389. (Pubitemid 41500611)
100. Dolman, R.C.; Deacon, G.B.; Hambley, T.W. Studies of the binding of a series of platinum(IV) complexes to plasma proteins. J. Inorg. Biochem., 2002, 88(3-4), 260-267. (Pubitemid 34207839)
101. Wong, E.; Giandomenico, C.M. Current status of platinum-based antitumor drugs. Chem. Rev., 1999, 99(9), 2451-2466.
102. Pendyala, L.; Greco, W.; Cowens, J.W.; Madajewicz, S.; Creaven, P.J. Pharmacokinetics of cis-dichloro-trans-dihydroxy-bisisopropylamine platinum IV (CHIP) in patients with advanced cancer. Cancer Chemother. Pharmacol., 1983, 11(1), 23-28. (Pubitemid 13039146)
103. Petros, W.P.; Chaney, S.G.; Smith, D.C.; Fangmeier, J.; Sakata, M.; Brown, T.D.; Trump, D.L. Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial. Cancer Chemother. Pharmacol., 1994, 33(4), 347-354. (Pubitemid 24033061)
104. Wang, B.; Wang, Z.; Feng, W.; Wang, M.; Hu, Z.; Chai, Z.; Zhao, Y. New methods for nanotoxicology: synchrotron radiation-based techniques. Anal. Bioanal. Chem., 2010, 398(2), 667-676.
105. Jenkins, R. X-ray Fluorescence Spectrometry, 2nd ed.; John Wiley: New York, 1999.
106. Sakurai, H.; Okamoto, M.; Hasegawa, M.; Satoh, T.; Oikawa, M.; Kamiya, T.; Arakawa, K.; Nakano, T. Direct visualization and quantification of the anticancer agent, cis-diamminedichloroplatinum( II), in human lung cancer cells using in-air microparticleinduced X-ray emission analysis. Cancer Sci., 2008, 99(5), 901-904. (Pubitemid 351997591)
107. Feldkamp, J.M.; Schroer, C.G.; Patommel, J.; Lengeler, B.; Günzler, T.F.; Schweitzer, M.; Stenzel, C.; Dieckmann, M.; Schroeder, W.H. Compact X-ray microtomography system for element mapping and absorption imaging. Rev. Sci. Instrum., 2007, 78(7), 073702.
108. Hall, M.D.; Alderden, R.A.; Zhang, M.; Beale, P.J.; Cai, Z.; Lai, B.; Stampfl, A.P.; Hambley, T.W. The fate of platinum(II) and platinum(IV) anti-cancer agents in cancer cells and tumours. J. Struct. Biol., 2006, 155(1), 38-44. (Pubitemid 43867317)
109. Hall, M.D.; Dillon, C.T.; Zhang, M.; Beale, P.; Cai, Z.; Lai, B.; Stampfl, A.P.; Hambley, T.W. The cellular distribution and oxidation state of platinum(II) and platinum(IV) antitumour complexes in cancer cells. J. Biol. Inorg. Chem., 2003, 8(7), 726-7232.
110. Chen, K.G.; Valencia, J.C.; Lai, B.; Zhang, G.; Paterson, J.K.; Rouzaud, F.; Berens, W.; Wincovitch, S.M.; Garfield, S.H.; Leapman, R.D.; Hearing, V.J.; Gottesman, M.M. Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. Proc. Natl. Acad. Sci. USA, 2006, 103(26), 9903-9907. (Pubitemid 43993595)
111. Shimura, M.; Saito, A.; Matsuyama, S.; Sakuma, T.; Terui, Y.; Ueno, K.; Yumoto, H.; Yamauchi, K.; Yamamura, K.; Mimura, H.; Sano, Y.; Yabashi, M.; Tamasaku, K.; Nishio, K.; Nishino, Y.; Endo, K.; Hatake, K.; Mori, Y.; Ishizaka, Y.; Ishikawa, T. Element array by scanning X-ray fluorescence microscopy after cisdiamminedichloro-platinum(II) treatment. Cancer Res., 2005, 65(12), 4998-5002. (Pubitemid 40827304)
112. Ilari, A.; Savino, C. Protein structure determination by X-ray crystallography. Methods Mol. Biol., 2008, 452(1), 63-87.
113. Takahara, P.M.; Frederick, C.A.; Lippard, S.J. Crystal structure of the anticancer drug cisplatin bound to duplex DNA. J. Am. Chem. Soc., 1996, 118(49), 12309-12321. (Pubitemid 27006798)
114. Takahara, P.M.; Rosenzweig, A.C.; Frederick, C.A.; Lippard, S.J. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature, 1995, 377(6550), 649-652.
115. Gelasco, A.; Lippard, S.J. NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) d(GpG) intrastrand cross-link, the major adduct of the anticancer drug cisplatin. Biochemistry, 1998, 37(26), 9230-9239. (Pubitemid 28307676)
116. Jamieson, E.R.; Lippard, S.J. Structure, Recognition, and Processing of Cisplatin-DNA Adducts. Chem. Rev., 1999, 99(9), 2467-298.
117. Pil, P.M.; Lippard, S.J. Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science, 1992, 256(5054), 234-237.
118. Grosschedl, R.; Giese, K.; Pagel, J. HMG domain proteins: architectural elements in the assembly of nucleoprotein structures. Trends Genet., 1994, 10(3), 94-100. (Pubitemid 24075089)
119. He, Q.; Liang, C.H.; Lippard, S.J. Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc. Natl. Acad. Sci. USA, 2000, 97(11), 5768-5772. (Pubitemid 30367473)
120. Zamble, D.B.; Mu, D.; Reardon, J.T.; Sancar, A.; Lippard, S.J. Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry, 1996, 35(31), 10004-10013. (Pubitemid 26269915)
121. Ohndorf, U.M.; Rould, M.A.; He, Q.; Pabo, C.O.; Lippard, S.J. Basis for recognition of cisplatin-modified DNA by high-mobilitygroup proteins. Nature, 1999, 399(6737), 708-712. (Pubitemid 29289069)
122. He, Q.; Ohndorf, U.M.; Lippard, S.J. Intercalating residues determine the mode of HMG1 domains A and B binding to cisplatinmodified DNA. Biochemistry, 2000, 39(47), 14426-1435.
123. Sherman, S.E.; Gibson, D.; Wang, A.H.; Lippard, S.J. X-ray structure of the major adduct of the anticancer drug cisplatin with DNA: cis-[Pt(NH3) 2(d(pGpG))]. Science, 1985, 230(4724), 412-417. (Pubitemid 16192555)
124. Sherman, S.E.; Gibson, D.; Wang, A.H.J.; Lippard, S.J. Crystal and molecular structure of cis-Pt(NH3)2d(pGpG), the principal adduct formed by cis-diamminedichloroplatinum(II) with DNA. J. Am. Chem. Soc., 1988, 110(22), 7368-7381. (Pubitemid 18260549)
125. Hallensleben, K.; Raida, M.; Habermehl, G. Identification of a new metabolite of macrolide immunosuppressant, like rapamycin and SDZ RAD, using high performance liquid chromatography and electrospray tandem mass spectrometry. J. Am. Soc. Mass Spectrom., 2000, 11(6), 516-525. (Pubitemid 34521239)
126. Yu, L.J.; Chen, Y.; DeNinno, M.P.; O'Connell, T.N.; Hop, C.E.C.A. Identification of a novel glutathione adduct of diclofenac, 4′-hydroxy- 2′-glutathion-deschloro-dichlofenac, upon incubation with human liver microsomes. Drug Metab. Dispos., 2005, 33(4), 484-488. (Pubitemid 40393189)
127. Hop, C.E.C.A.; Chen, Y.; Yu, L.J. Uniformity of ionization response of structurally diverse analytes using a chip-based nanoelectrospray ionization source. Rapid Commun. Mass Spectrom., 2005, 19(21), 3139-30342.
128. Wong, M.C.Y.; Lee, W.T.K.; Wong, J.S.Y.; Frost, G.; Lodge, J. An approach towards method development for untargeted urinary metabolite profiling in metabonomic research using UPLC/QToF MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2008, 871(2), 341-348.
129. Gika, H.G.; Macpherson, E.; Theodoridis, G.A.; Wilson, I.D. Evaluation of the repeatability of ultra-performance liquid chromatography- TOF-MS for global metabolic profiling of human urine samples. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2008, 871(2), 299-305.
130. Staack, R.F.; Varesio, E.; Hopfgartner, G. The combination of liquid chromatography/tandem mass spectrometry and chip-based infusion for improved screening and characterization of drug metabolites. Rapid Commun. Mass Spectrom., 2005, 19(5), 618-626. (Pubitemid 40332757)